학술논문
Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: A 16-week, randomised, open-label, phase 2 trial
Document Type
Article
Author
Source
In: The Lancet . (The Lancet, March 12-18, 2011, 377(9769):924-931)
Subject
Language
English
ISSN
01406736